BioNTech Investor Presentation Deck
Taking mRNA from vision to reality
17
BNT162b2
BONTech COVID-19 V
a vial contains 5 doses of
ular use, Contains no pre
de Emergency Use Auth
MEFORE USE.
hours after dilution wher
2 25°C (35 to 77°F
and time
COMIRNATYⓇ
COVID-19 mRNA Vaccine
First ever approved mRNA therapy¹
Fastest vaccine development in medical history
One of the most successful pharmaceutical launches in history²
>1 bn individuals vaccinated in 2021
COMIRNATY market share³: USA: -74%; EU: -80%
Millions of cases of severe illness or death likely averted 4
Trillions of dollars of global economic impact5
¹Approved for emergency use/temporary supply or Conditional Marketing Authorization in more than 90 countries worldwide including the U.S. and EU, December 2021
2 Doses shipped in first year after launch; 3 As of mid December 2021; 4 Eric C. Schneider et al., The U.S. COVID-19 Vaccination Program at One Year: How Many Deaths and Hospitalizations Were
Averted? (Commonwealth Fund, December 2021); European Centre for Disease Prevention and Control; 5Statista
Pfizer
BIONTECHView entire presentation